Related Experiment Video
Updated: Sep 23, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Daidzein attenuates urinary bladder dysfunction in streptozotocin-induced diabetes in rats by NOX-4 and RAC-1
Ankit P Laddha1, Yogesh A Kulkarni2
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (West), Mumbai, 400056, India.
Abstract:
Reactive oxygen species via NADPH oxidase (NOX) activation are involved in the pathogenesis of many disease conditions such as diabetes and its complications. In the present study, we have examined the effect of daidzein in the management of diabetic cystopathy. Diabetes was induced in male Sprague Dawley rats via intraperitoneal injection of streptozotocin (STZ) at a dose of 55 mg/kg. After 6 weeks of diabetes induction, animals were treated with daidzein orally at a dose of 25, 50, and 100 mg/kg for 4 weeks. Diabetic animals showed increase (p < 0.001) in bladder capacity (4.32 ± 0.43 mL) and residual volume (2.53 ± 0.19 mL) when compared with normal control animals (2.10 ± 0.40 mL and 0.51 ± 0.12 mL res). Treatment with daidzein at dose of 50 and 100 mg/kg significantly reduced the elevated bladder capacity (2.91 ± 0.11 mL, p < 0.01 and 2.65 ± 1.13 mL, p < 0.001) and residual volume (1.40 ± 0.15 mL, p < 0.001 and 1.15 ± 0.05 mL, p < 0.001). Daidzein-treated animals also showed improvement in voiding efficiency. Elevated threshold and baseline pressure were also found to be reduced in diabetic animals after 4 weeks of daidzein treatment. Daidzein treatment also prevented the loss of antioxidant enzymes in the urinary bladder and also reduced the expression of NOX-4 and RAC-1 in the bladder. From the results, it can be concluded that daidzein showed a beneficial effect on urinary bladder dysfunction in diabetic animals.
Insights
Daidzein treatment improved urinary bladder dysfunction in diabetic rats by reducing bladder capacity and residual volume. This suggests daidzein is a potential therapeutic agent for managing diabetic cystopathy.
Area of Science:
- Biomedical Sciences
- Pharmacology
- Urology
Background:
- Reactive oxygen species (ROS) and NADPH oxidase (NOX) activation contribute to diabetes complications.
- Diabetic cystopathy, a common complication, affects bladder function.
- Daidzein's therapeutic potential in managing diabetic complications warrants investigation.
Purpose of the Study:
- To investigate the efficacy of daidzein in treating diabetic cystopathy in a rat model.
- To evaluate the impact of daidzein on bladder function parameters in diabetic rats.
- To explore the underlying mechanisms, including oxidative stress and NOX pathway modulation.
Main Methods:
- Diabetes was induced in male Sprague Dawley rats using streptozotocin (STZ).
- Animals were treated with varying doses of daidzein (25, 50, 100 mg/kg) for four weeks.
- Bladder capacity, residual volume, voiding efficiency, and oxidative stress markers were assessed.
Main Results:
- Diabetic rats exhibited increased bladder capacity and residual volume, which were significantly reduced by daidzein treatment (50 and 100 mg/kg).
- Daidzein improved voiding efficiency and reduced elevated bladder threshold and baseline pressure.
- Treatment prevented the loss of antioxidant enzymes and decreased the expression of NOX-4 and RAC-1 in the bladder.
Conclusions:
- Daidzein demonstrates significant therapeutic benefits for urinary bladder dysfunction in diabetic rats.
- Daidzein ameliorates diabetic cystopathy by mitigating oxidative stress and modulating the NOX pathway.
- Daidzein holds promise as a potential treatment for diabetic cystopathy.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
01:16Antihypertensive Drugs: Action of Diuretics
01:25Antihypertensive Drugs: Direct Renin Inhibitors